<DOC>
	<DOCNO>NCT00376961</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop dividing . Bortezomib may stop growth cancer cell block enzymes need cell growth . Giving rituximab together combination chemotherapy bortezomib may kill cancer cell . Giving bortezomib maintenance therapy may keep cancer progress . PURPOSE : This phase II trial study well give rituximab together combination chemotherapy bortezomib follow bortezomib alone work treat patient newly diagnose mantle cell lymphoma .</brief_summary>
	<brief_title>S0601 Rituximab , Combination Chemotherapy , Bortezomib Followed Bortezomib Alone Treating Patients With Newly Diagnosed Mantle Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine 2-year progression-free survival rate patient newly diagnose mantle cell lymphoma treat induction therapy comprise rituximab , cyclophosphamide , doxorubicin hydrochloride , vincristine , prednisone , bortezomib follow bortezomib maintenance ( VM ) therapy . Secondary - Determine response rate ( complete , complete unconfirmed , partial response ) patient treat regimen . - Determine toxicity VM patient . OUTLINE : This multicenter study . - Induction therapy : Patients receive R-CHOP-V induction therapy comprise rituximab IV ≤ 6 hour , cyclophosphamide IV 15-45 minute , doxorubicin hydrochloride IV 5-20 minute , vincristine IV 5-15 minute day 1 ; oral prednisone daily day 1-5 ; bortezomib IV 30-90 minute day 1 4 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After completion 6 course , patient stable disease well proceed bortezomib maintenance therapy . - Maintenance therapy : Beginning 3 month completion R-CHOP-V induction therapy , patient receive bortezomib IV day 1 , 4 , 8 , 11 . Treatment repeat every 3 month 8 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 4 year annually 3 year . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm mantle cell lymphoma ( MCL ) meeting follow criterion : Stage IIIIV bulky stage II disease Confirmation positivity follow phenotype immunohistochemistry flow cytometry : Cluster differentiation antigen 19 ( CD19 ) ( CD20 ) Cyclin D1 OR evidence ( 11 ; 14 ) translocation cytogenetic analysis fluorescent situ hybridization Newly diagnose , previously untreated disease Bidimensionally measurable disease conventional technique No nonmeasurable disease Adequate tumor tissue original diagnostic specimen available Tissue obtain needle aspiration cytology allow No clinical evidence central nervous system ( CNS ) involvement lymphoma Coregistration protocols SWOG8947 SWOG8819 strongly encourage PATIENT CHARACTERISTICS : Zubrod performance status 02 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No peripheral neuropathy ≥ grade 2 No hypersensitivity bortezomib , boron , mannitol No prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated stage I II cancer patient currently complete remission , cancer patient disease free past 5 year HIV negative PRIOR CONCURRENT THERAPY : No prior chemotherapy , radiotherapy , antibody therapy lymphoma More 14 day since prior investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
</DOC>